Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients DOI Creative Commons
Sofía Haselgruber, Daniel Muñoz‐Barba,

Francisco Javier León-Pérez

et al.

International Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 15, 2024

Abstract Introduction Therapeutic burden (TB) has been identified as a potential predictor of response to biologic therapy in hidradenitis suppurativa (HS). We aim analyze the determinants TB real‐world clinical settings among HS patients explain this concept and its utility an additional tool for guiding therapeutic decision‐making. Methods conducted cross‐sectional study including all consecutive attending specialized clinic between 2017 2024. The primary variable was TB, defined cumulative sum prior systemic treatment cycles surgical interventions HS. analyzed whether sociodemographic or factors were associated with higher TB. Results included 557 patients. Of these, 50.81% women, mean age 41.87 (14.19) years. Most (62.30%) referred from general dermatology consultations. disease duration 17.52 (11.51) Regarding severity, 46.50% presented Hurley II, 42.19% had IHS‐4 score 4 10. Before their baseline visit, 9.70% received biological therapy, mostly adalimumab (88.89%). 2.42 (2.25) medical and/or interventions. Referral other hospital departments, older age, longer duration, greater presence pilonidal sinus, significantly Conclusions Our findings suggest that comprehensively captures severity progression factors. This metric could prove valuable aiding decision‐making by indicating when change might be necessary.

Language: Английский

Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients DOI Creative Commons
Sofía Haselgruber, Daniel Muñoz‐Barba,

Francisco Javier León-Pérez

et al.

International Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 15, 2024

Abstract Introduction Therapeutic burden (TB) has been identified as a potential predictor of response to biologic therapy in hidradenitis suppurativa (HS). We aim analyze the determinants TB real‐world clinical settings among HS patients explain this concept and its utility an additional tool for guiding therapeutic decision‐making. Methods conducted cross‐sectional study including all consecutive attending specialized clinic between 2017 2024. The primary variable was TB, defined cumulative sum prior systemic treatment cycles surgical interventions HS. analyzed whether sociodemographic or factors were associated with higher TB. Results included 557 patients. Of these, 50.81% women, mean age 41.87 (14.19) years. Most (62.30%) referred from general dermatology consultations. disease duration 17.52 (11.51) Regarding severity, 46.50% presented Hurley II, 42.19% had IHS‐4 score 4 10. Before their baseline visit, 9.70% received biological therapy, mostly adalimumab (88.89%). 2.42 (2.25) medical and/or interventions. Referral other hospital departments, older age, longer duration, greater presence pilonidal sinus, significantly Conclusions Our findings suggest that comprehensively captures severity progression factors. This metric could prove valuable aiding decision‐making by indicating when change might be necessary.

Language: Английский

Citations

1